Back to Authors

Wisniewski, Stephen J

Mayo Clinic

Departments of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA.

Citations 2

A phase 1 clinical trial shows safe, sustained, AAV-mediated expression of IL-1Ra in the human osteoarthritic knee joint
Vega, Rodolfo E. De la , Sellon, Jacob L. , Smith, Jay , Wisniewski, Stephen, Jurisson, Mary L. , Frick, Matthew A., Scrabeck, Tyson L., Block, Julie B., Mills, Candee J. , Pohlkamp, Zachary W., Coenen, Michael J., Hawse, Gresin P. , Abdul, Temilola Y. , Conaghan, Philip G. , Keravala, Annahita, Robbins, Paul D. , Ghivizzani, Steven C. , Evans, Christopher H. , De La Vega, Rodolfo E , Wisniewski, Stephen J, Conaghan, Philip , Chalberg, Thomas W , Robbins, Paul D , Ghivizzani, Steven C , Evans, Christopher H , Block, Julie B.

Science Translational Medicine | June 4, 2025 | Volume: 17 | Issue: 801 | Pages: No page available

10.1126/scitranslmed.adu9804 Get It

Osteoarthritis (OA) is a major global health problem with no disease-modifying therapies. Interleukin-1 (IL-1) is a critical cytokine associated with the pathophysiology of OA and can be inhibited by IL-1 receptor antagonist (IL-1Ra). Here, we tested the delivery of a gene therapeutic encoding the human IL-1Ra to the knee in a phase 1, open-label clinical trial that enrolled nine patients with radiographic knee OA. The IL-1Ra gene was delivered by a self-complementary (sc)–recombinant adeno-associated virus (rAAV) serotype 2.5 (sc-rAAV2.5IL-1Ra) by intra-articular injection into an index knee at one of three doses: low [1 × 10 11 viral genomes (vg)], mid (1 × 10 12 vg), or high (1 × 10 13 vg). The primary outcome was safety. There were no serious adverse events (AEs) related to sc-rAAV2.5IL-1Ra. Two AEs occurred that were possibly related to the vector. Both were effusions with increased pain and resolved with conservative treatment. sc-rAAV2.5IL-1Ra did not cause changes in vital signs, physical findings, or clinical laboratory measures. Less than 1% of the injected dose of sc-rAAV2.5IL-1Ra vg was detected in circulation after 1 day and was cleared within a week. Titers of neutralizing antibodies to AAV2.5 rose in serum and synovial fluid. In all cases, IL-1Ra concentration increased in the synovial fluid, and IL-1Ra concentrations remained elevated after 1 year. Baseline pain and function scores improved during the study. Therefore, we found that intra-articular gene therapy with sc-rAAV2.5IL-1Ra was safe. The sustained increase in local IL-1Ra in human knee joints supports the further clinical examination of this therapy to provide therapeutic benefit in OA.
Accuracy of Ultrasound Compared to Magnetic Resonance Imaging in the Diagnosis of Thumb Ulnar Collateral Ligament Injuries
Moore, Brittany J. , Iafrate, Julia L., Kakar, Sanjeev , Wisniewski, Stephen, Murthy, Naveen S. , Smith, Jay , Wisniewski, Stephen J, Kakar, Sanjeev , Murthy, Naveen S

Journal of Ultrasound in Medicine | September 24, 2020 | Volume: 40 | Issue: 6 | Pages: 1251-1257

10.1002/jum.15491 Get It

This prospective case series compared the accuracy of ultrasound (US) to magnetic resonance imaging (MRI) in differentiating complete displaced (CD) thumb ulnar collateral ligament (UCL) tears from nondisplaced injuries in 10 patients with suspected traumatic thumb UCL injuries. Ultrasound identified 100% (2 of 2) of MRI‐documented CD tears, both of which were further confirmed during surgical repair. Ultrasound identified the absence of CD tears in the remaining 8 patients. Although MRI is the reference standard imaging modality for characterizing thumb UCL injuries, ultrasound should be considered an accurate, cost‐effective, and alternative imaging modality to differentiate surgical versus nonsurgical thumb UCL injuries.